

Dr. Balevic, *et al*, reply

Stephen J. Balevic, MD, MHS; Christoph P. Hornik, MD, PhD; Thomas P. Green, MD, MS; Megan E.B. Clowse, MD, MPH; Daniel Gonzalez, PharmD, PhD; Anil R. Maharaj, PhD; Laura E. Schanberg, MD; Amanda M. Eudy, PhD; Geeta K. Swamy, MD; Brenna L. Hughes, MD, MSc; Michael Cohen-Wolkowicz, MD, PhD

Index terms: COVID-19; pregnancy; hydroxychloroquine; systemic lupus erythematosus, rheumatic diseases

From the Department of Rheumatology and Immunology, Duke University School of Medicine, Durham, NC USA (Drs. Balevic, Clowse, Eudy); Duke Clinical Research Institute, Durham, NC USA (Drs. Balevic, Hornik, Maharaj, Schanberg, Cohen-Wolkowicz); Department of Pediatrics, Duke University School of Medicine, Durham, NC USA (Drs. Balevic, Hornik, Schanberg, Cohen-Wolkowicz); Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Evanston, IL USA (Dr. Green); Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC USA (Dr. Gonzalez); Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynecology, Duke University School of Medicine (Drs. Swamy, Hughes)

Sources of funding: Salary and/or research support for this project was provided by the Rheumatology Research Foundation’s Scientist Development Award, the Thrasher Research Fund, the Childhood Arthritis and Rheumatology Research Alliance/Arthritis Foundation, the Derfner Foundation, NIGMS/NICHD (2T32GM086330-06), NICHD (5R01-HD076676-04, HHSN275201000003I), and a Duke Health/Private Diagnostic Clinic ENABLE grant.

Conflict of interest disclosures: S.J.B receives support from the National Institutes of Health (5R01-HD076676-04, 1R01HD083003-01, HHSN275201000003I, HHSN275201800003I, HHSN272201500006I, 5U24-TR001608-03), FDA (5U18FD006298-03), PCORI, the Rheumatology Research Foundation’s Scientist

Development Award, the Thrasher Research Fund, the Childhood Arthritis and Rheumatology Research Alliance/Arthritis Foundation, and consulting for UCB.

Dr. Hornik receives salary support for research from National Institute for Child Health and Human Development (NICHD) (1K23HD090239; R13HD102136), the National Heart Lung and Blood Institute (NHLBI) (R61/R33HL147833), the US Food and Drug Administration (1R01-FD006099, PI Laughon; and 5U18-FD006298, PI: Benjamin), the U.S. government for his work in pediatric clinical pharmacology (Government Contract HHSN275201800003I, PI: Benjamin under the Best Pharmaceuticals for Children Act), the non-profit Burroughs Wellcome Fund, and other sponsors for drug development in adults and children (<https://dcric.org/about-us/conflict-of-interest/>).

T.P.G. reports no relevant disclosures.

M.E.B.C. reports no relevant disclosures.

D.G. receives support for research from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD, 5R01HD096435).

A.M. receives research support from the Thrasher Research Fund (www.thrasherresearch.org).

L.E.S. receives support for research from the National Institutes of Health (U19AR069522), PCORI (8177), SOBI, BMS, the Childhood Arthritis and Rheumatology Research Alliance. She is on the DSMB for investigational product trials for UCB (Cimzia) and Sanofi (sarilimumab). Samples used in this publication where collected as part of NIH/NIAMS N01-AR-2-2265.

A.M.E. receives support from National Institutes of Health, National Center for Advancing Translational Sciences (1KL2TR002554).

G.K.S. receives support for research from the National Institutes of Health (UG1 HD068258-06, HHSN272201300017I, 1UL1TR002553-01, R21AI132677) and the Centers for Disease Control and Prevention (200-2012-53663). She chairs Independent Data Monitoring Committees (IDMCs) for Pfizer (Group B strep vaccine trials) and GlaxoSmithKline (RSV vaccine trials).

B.L.H. reports no relevant disclosures.

M.C.W. receives support for research from the National Institutes of Health (1R01-HD076676-01A1 and 1K24-AI143971), National Institute of Allergy and Infectious Diseases (HHSN272201500006I and HHSN272201300017I), NICHD (HHSN275201000003I), U.S. Food and Drug Administration (5U18-FD006298), and industry for drug development in adults and children.

Address for correspondence: Stephen J. Balevic, MD, MHS; Department of Rheumatology and Immunology, Duke University School of Medicine, 2301 Erwin Road, CHC; Tel: 919-684-6575; Fax:919-684-6616; Email: stephen.balevic@duke.edu

To the Editor:

We read with great interest the very thoughtful commentary by Drs. Joob and Wiwanitkit. We agree with the authors that, despite conflicting clinical data to date, it is possible that HCQ may have a protective effect in the setting of COVID-19. More importantly, we agree that optimal HCQ dosage and timing is a critical underpinning for clinical trials. However, we highlight several considerations regarding treatment with high dose HCQ.

In order to optimize dosing, the relationship between drug concentration in the target tissue and response must be well characterized. Because the precise mechanism of action of HCQ for SARS-CoV-2 is unknown, current dosing strategies are based on extrapolating the in-vitro antiviral activity targets (e.g., EC50, EC100). Herein lies one of the first challenges; the reported EC50 target for inhibiting viral replication varies in different reports (0.72-17.31 μM).^{1,2} Based on in-vitro EC50 targets, dosages of HCQ 400 mg orally every 12 hours for 2 doses followed by 200 mg every 12 hours to achieve target unbound lung concentrations has been proposed.¹ However, the authors relied on animal-derived lung partition coefficients for HCQ, and it was unclear how they accounted for differences in the fraction of unbound drug in tissue compared to plasma.¹ Differences in these assumptions significantly alter whether the proposed dosing would achieve target concentrations.³ Similarly, we modeled total serum concentrations and observed that only the lowest EC50 target (0.72 μM) is achievable in serum using proposed loading doses, and all concentrations were significantly less than those needed for complete viral inhibition.⁴

Although our analysis suggests that most in-vitro target concentrations cannot be achieved in plasma and pulmonary interstitial fluid even with higher dosing, this does not preclude a potential benefit for HCQ in the setting of COVID-19. In addition to possible anti-inflammatory benefits, intracellular lung concentrations may be critical for the drug's potential antiviral effect. HCQ appears to block intracellular transport of SARS-CoV-2, with only 0.03% of virions in HCQ treated cells localizing to endolysosomes, compared to 34.3% in untreated cells.² Because animal studies suggest substantially higher HCQ concentrations in lung tissue compared to plasma, it is possible that antiviral target concentrations can be achieved in the lungs cells compared to interstitial fluid with conventional dosing.^{2,5} However, because HCQ accumulates in lung tissue over several months,⁵ the duration of therapy (as opposed to the dose) may be the key to understanding the drug's potential in COVID-19. In addition, we are aware of early reports that suggest patients with lupus and SARS-CoV-2 infection

develop severe COVID-19 at a similar frequency regardless of prior HCQ use, underscoring the importance of further study.⁶

References:

1. Yao X, Ye F, Zhang M, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). *Clin Infect Dis*. 2020.
2. Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. *Cell Discov*. 2020;6:16.
3. Arnold SL, Buckner F. Hydroxychloroquine for treatment of SARS-CoV-2 infection? Improving our confidence in a model-based approach to dose selection. *Clin Transl Sci*. 2020.
4. Balevic SJ, Hornik CP, Green TP, et al. Hydroxychloroquine in Patients with Rheumatic Disease Complicated by COVID-19: Clarifying Target Exposures and the Need for Clinical Trials. *J Rheumatol*. 2020.
5. McChesney EW. Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate. *Am J Med*. 1983;75(1A):11-18.
6. Konig MF, Kim AH, Scheetz MH On behalf of the COVID-19 Global Rheumatology Alliance, et al. Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19. *Annals of the Rheumatic Diseases* Published Online First: 07 May 2020. doi: 10.1136/annrheumdis-2020-217690.